Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PR-Negative Breast Cancer”

270 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 270 results

Testing effectiveness (Phase 2)WithdrawnNCT03872505
What this trial is testing

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cedars-Sinai Medical Center
Early research (Phase 1)Ended earlyNCT01238133
What this trial is testing

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+6 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Ended earlyNCT01319539
What this trial is testing

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+11 more
National Cancer Institute (NCI) 12
Early research (Phase 1)Ended earlyNCT01071564
What this trial is testing

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+5 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Study completedNCT05159778
What this trial is testing

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Who this might be right for
Malignant Neoplasm of Breast
HiberCell, Inc. 26
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Early research (Phase 1)Ended earlyNCT06264921
What this trial is testing

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorSolid Tumor, AdultAdvanced Solid Tumor+26 more
NiKang Therapeutics, Inc. 23
Early research (Phase 1)Ended earlyNCT01281163
What this trial is testing

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Positive+4 more
National Cancer Institute (NCI) 4
Large-scale testing (Phase 3)Study completedNCT00022516
What this trial is testing

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 1,086
Testing effectiveness (Phase 2)Ended earlyNCT00542191
What this trial is testing

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Leo W. Jenkins Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT00785291
What this trial is testing

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+6 more
National Cancer Institute (NCI) 799
Not applicableWithdrawnNCT01292083
What this trial is testing

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Who this might be right for
Recurrent Breast CancerStage IA Breast CancerStage IB Breast Cancer+6 more
University of Southern California
Testing effectiveness (Phase 2)Active Not RecruitingNCT02398773
What this trial is testing

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Who this might be right for
HER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI) 99
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Study completedNCT00577122
What this trial is testing

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerProgesterone Receptor-negative Breast CancerRecurrent Breast Cancer+1 more
Indiana University 30
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Testing effectiveness (Phase 2)Looking for participantsNCT04698252
What this trial is testing

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Who this might be right for
Breast Cancer
Instituto do Cancer do Estado de São Paulo 74
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Load More Results